Inhibition
Inhibition is the reduction or prevention of a biological process, molecular interaction, cellular activity, or physiological response.
Inhibition is the reduction or prevention of a biological process, molecular interaction, cellular activity, or physiological response. In biomedical research, it commonly refers to suppressing the activity of an enzyme, receptor, signaling pathway, transcriptional regulator, metabolic reaction, inflammatory process, or cell population. Inhibition may be produced by a small-molecule inhibitor, antibody, genetic intervention, therapeutic procedure, or an endogenous regulatory mechanism.
The magnitude of inhibition is often assessed using measures such as the half-maximal inhibitory concentration (IC50), which describes the concentration of an agent required to reduce a defined activity by 50% under specified experimental conditions. Its biological interpretation depends on the target, assay system, selectivity, exposure, and relationship between target suppression and the disease phenotype. The recent literature represented here places inhibition within the broad theme of diverse molecular therapeutics, including enzyme discovery, cancer treatment combinations, metabolic regulation, fibrosis, neuroinflammation, and modulation of stress- and inflammation-associated pathways. Related concepts include inhibitor design, binding, activation, signaling, molecular docking, potency, cytotoxicity, apoptosis, proliferation, migration, and pathway validation.
Rebuilt from PubMed 18 Sept 2026 · no new papers today
Where the papers sit
14 papers study inhibition directly. Those 14 do not group into themes. The papers address unrelated targets, from HSV-1 UL21 and kallikreins to cancer pathways, arterial calcification, and the POMC-ACTH-cortisol axis. They share inhibitory intervention as a method, not a biological question, so no common direction emerges. They are no more alike than papers drawn from anywhere in the corpus.
Recent Findings on inhibition
Diverse Molecular Inhibition: Natural-product scaffolds targeted HSV-1 UL21, while fragment-based screening produced ligand-efficient KLK6 and KLK7 inhibitors 42748207Sep42734496Sep. In cancer models, PARP inhibition enhanced HER3-DXd activity, while CDK8/19 inhibition prevented adaptive resistance to CDK4/6 inhibitors 42628527Aug42617601Aug. Bronopol, electroacupuncture, and traditional Chinese medicine formulas suppressed disease-linked signaling in pulmonary fibrosis, spinal cord injury, atherosclerosis, and hypertensive nephropathy 42276357Jun42251832Jun42081953May42035996Apr. Other studies connected inhibition with gut-brain endocrine regulation, vascular calcification, lipid metabolism, and post-stroke neuronal protection 42624113Aug42531909Jul42500328Jul42092579May. Results varied across models: Apicidin preserved neuronal ultrastructure whereas DMOG mainly stabilized vascular integrity, and LXQ-87 showed limited xenograft benefit despite strong cellular activity 42219139May42320116Jun.
Written from 14 PubMed abstracts, each one cited by PMID above. Published: 2026-09-17. Last written: 2026-09-18 by GPT. Drafted by language models from published abstracts; not medical advice.